Michael G. Atieh - Director | Chubb (CB) Executive Profile & Compensation

About Michael G. Atieh

Independent director of Chubb Limited (CB); age 71; on the Board since 1991 (34 years). Former Executive Vice President and Chief Financial and Business Officer at Ophthotech; extensive finance, operating, and audit experience across biopharma, technology, and Fortune 50 pharma; Chubb Risk & Finance Committee member. Determined independent under NYSE standards; Board met five times in 2024, and all directors (including Atieh) attended at least 75% of meetings .

Past Roles

Organization	Role	Tenure	Committees/Impact
Ophthotech Corporation	EVP & Chief Financial and Business Officer	Sep 2014–Mar 2016	Senior finance leadership in biopharma
Eyetech Inc.	Executive Chairman	Feb 2009–Feb 2012	Led specialty pharma; governance leadership
OSI Pharmaceuticals	EVP & CFO	Jun 2005–Dec 2008	CFO; prior OSI Director & Audit Chair (2003–2005)
Dendrite International	SVP & CFO; later Group President	Oct 2000–Dec 2001; Jan 2002–Feb 2004	Finance and operating leadership in software
Merck & Co., Inc.	Treasurer; VP Public Affairs; SVP Merck-Medco; VP U.S. Human Health	Apr 1990–Sep 2000	Finance, managed care, and operations leadership
Ernst & Young	Audit Manager	Prior to 1990	Audit expertise; basis for financial oversight

External Roles

Organization	Role	Tenure	Committees/Impact
Immatics N.V.	Director; Audit Committee Chair	Current	Audit oversight in clinical-stage biopharma
Oyster Point Pharma, Inc.	Director; Audit Committee Chair	Oct 2020–Jan 2023	Audit leadership pre-acquisition
electroCore, Inc.	Director	Jun 2018–Jun 2022	Governance in medical technology
Theravance Biopharma, Inc.	Director	Jun 2014–Apr 2015	Board member in biopharma
OSI Pharmaceuticals, Inc.	Director; Audit Committee Chair	Jun 2003–May 2005	Audit oversight

Board Governance

Committee assignments: Risk & Finance Committee member; committee met 4 times in 2024 and oversees ERM, capital structure, and investment risk .
Independence: Board determined Atieh independent; 93% of nominee slate independent; independent directors hold regular executive sessions .
Attendance: Board met five times in 2024; all directors attended ≥75% of their Board and committee meetings .
AGM election support (2025): Votes for 317,795,932; against 12,837,296; abstain 308,481; broker non-votes 27,048,017 .
Director commitments policy: Corporate Governance Guidelines and Articles limit directors to no more than four additional public company board/executive management affiliations; meaningful external commitment limitations enforced .

Fixed Compensation

Component (2024)	Amount	Detail
Cash retainer	$135,000	Paid quarterly
Equity grant (restricted stock)	$190,184	Granted at AGM; vests at next AGM; grant-date share price $264.88
Other compensation	$40,000	Matching charitable contributions (max)
Total	$365,184	Sum of above

Standard outside director parameters (2024): $325,000 total ($135,000 cash; $190,000 equity); committee chair fees apply where relevant (Atieh not a chair) .
Parameter updates effective 2025 AGM: cash retainer increased to $150,000; equity retainer to $225,000; Compensation Committee Chair fee to $30,000; special meeting fees eliminated .

Performance Compensation

Performance-Linked Elements	Status	Notes
Director pay tied to corporate performance targets	None	Board members (except CEO) receive fixed compensation; not tied to specific corporate results or performance targets

Other Directorships & Interlocks

Current public company: Immatics N.V. (Audit Chair) .
Prior public companies: Oyster Point Pharma (Audit Chair); electroCore; Theravance Biopharma; OSI Pharmaceuticals (Audit Chair) .
Related-party transactions: Proxy discloses related-party dealings primarily with BlackRock and Starr; no transactions disclosed involving Atieh .
Section 16(a) compliance: No delinquency noted for Atieh; disclosures cite other individuals for administrative corrections .

Expertise & Qualifications

Deep finance and audit expertise: Prior CFO roles (OSI, Ophthotech), audit manager at Ernst & Young, and multiple audit chair roles (including service as chair of Chubb’s audit committee historically and other public companies) .
Operating and commercial acumen: Merck senior roles in managed care, U.S. Human Health; Dendrite operating leadership; customer-facing responsibilities .
Risk oversight: Long tenure provides historical context for ERM; current service on Risk & Finance aligns with financial and risk management background .

Equity Ownership

Holder	Common Shares Beneficially Owned	Options (Exercisable ≤60 days)	Restricted Common Shares	Notes
Michael G. Atieh	16,475	—	718	Includes vested stock units payable immediately upon separation (16,475); additional deferred RSUs not included: 22,229 payable ≥6 months after separation; individual holdings constitute <1% of outstanding shares

Director ownership guidelines: Minimum five times cash retainer ($150,000 in 2025 → $750,000 minimum); all directors with ≥5 years of service satisfy requirements (Atieh qualifies) .
Hedging/pledging: Directors prohibited from hedging or new pledging of Chubb shares .

Governance Assessment

Board effectiveness: Atieh’s extensive CFO/audit background strengthens Risk & Finance oversight; consistent attendance and independence support governance quality .
Alignment: Mix of cash and annual restricted stock; robust director ownership guidelines met by long-serving directors; prohibition on hedging/pledging enhances alignment .
Conflicts/related-party exposure: No related-party transactions disclosed for Atieh; no Section 16 concerns noted; commitment limits mitigate overboarding risk .
Shareholder support signal: Strong re-election margin in 2025 AGM indicates investor confidence in his continued service and committee contribution .
RED FLAGS: None identified specific to Atieh (no related-party transactions, no attendance issues, no disclosure of pledging). Potential soft flag is very long tenure (34 years), which the Board addresses via refreshment and tenure balance; Board highlights 43% of nominees with ≤5 years tenure and regular evaluations .